Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Malta

European Innovation Council · Running

TargetMI A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction

Coordinator
Universita Ta Malta, Malta
Runs
1 October 2023 to 30 September 2028
Status
Running
EU funding
€4.0m
Total cost
€4.0m
Partners
2 organisations in 2 countries
Type
European Innovation Council
Grant agreement
101114924

What the project is doing

In the project's own words, from its summary on CORDIS.

In TargetMI we propose a high throughput multi-omic approach for rapid discovery of novel drug targets, biomarkers and risk algorithms, applied here to atherosclerosis, myocardial infarction (MI) and their risk factors. Cardiovascular disease is a major cause of death and morbidity worldwide. The causes of MI are highly complex involving genetic, lifestyle and environmental factors. Whilst much research effort has been invested in attempting to decipher these factors, clinical applications of findings are disappointingly few.

We will harness four -omic datasets (whole genome, transcriptomic, metabolomic and proteomic data) on 1000 highly phenotyped samples of the Maltese Acute Myocardial Infarction (MAMI) Study. These were collected from cases, controls and relatives of cases (including 80 families) with meticulous attention to preanalytical variables. We will identify intermediate phenotypes associated with risk of MI and its associated risk factors.

Using a combination of approaches including extreme phenotype and family-based approaches we will identify variants which robustly influence these intermediate phenotypes. The genes thus identified are potential drug targets that influence risk of MI via an intermediate phenotype and are applicable across all populations. They will be validated through various approaches including computational analysis, (using Mendelian randomisation and 10 year follow-up data), and functional work that includes using zebrafish as an animal model.

Machine learning algorithms will be used to analyse the multi-layered data to identify novel biomarkers and risk algorithms, including polygenic risk scores, for early risk prediction in the clinic. Quantitative targeted proteomic assays will be developed for further validation in other cohorts facilitating clinical use. Besides the increase in knowledge on the molecular etiology of MI, this powerful integrated strategy will bring rapid clinical translation of unprecedented multi-omic data.

Topics

Who is involved

OrganisationCityCountryRole
Universita Ta MaltaMsidaMaltaCoordinator
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI